| __timestamp | ImmunityBio, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 72471000 |
| Thursday, January 1, 2015 | 226206000 | 89204000 |
| Friday, January 1, 2016 | 94391000 | 106010000 |
| Sunday, January 1, 2017 | 53821000 | 137905000 |
| Monday, January 1, 2018 | 35463000 | 159888000 |
| Tuesday, January 1, 2019 | 46456000 | 158425000 |
| Wednesday, January 1, 2020 | 71318000 | 200677000 |
| Friday, January 1, 2021 | 135256000 | 304759000 |
| Saturday, January 1, 2022 | 102708000 | 377221000 |
| Sunday, January 1, 2023 | 129620000 | 336361000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, ImmunityBio, Inc. and Supernus Pharmaceuticals, Inc. have showcased contrasting strategies in this domain. From 2014 to 2023, ImmunityBio's SG&A expenses surged by approximately 2,900%, peaking in 2015, while Supernus Pharmaceuticals maintained a steadier growth, with a 365% increase over the same period. This disparity highlights ImmunityBio's aggressive expansion strategy compared to Supernus's more measured approach. Notably, in 2022, Supernus's SG&A expenses were nearly three times higher than ImmunityBio's, reflecting its larger market footprint. As these companies navigate the evolving healthcare landscape, their SG&A efficiency will remain a key indicator of their operational success and market adaptability.
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
AbbVie Inc. vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing argenx SE and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Genmab A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.